Dehydroxymethylepoxyquinomicin, a novel nuclear factor-κB inhibitor, prevents the development of cyclosporine A nephrotoxicity in a rat model
Authors:
- Shinya MoritaSMShinya Morita
- Kazunobu ShinodaKSKazunobu Shinoda
- Tadashi YoshidaTYTadashi Yoshida
- Masayuki ShimodaMSMasayuki Shimoda
- Yoshihiko KannoYKYoshihiko Kanno
- Ryuichi MizunoRMRyuichi Mizuno
- Hidaka KonoHKHidaka Kono
- Hiroshi AsanumaHAHiroshi Asanuma
- Ken NakagawaKNKen Nakagawa
- Kazuo UmezawaKUKazuo Umezawa
- Mototsugu OyaMOMototsugu Oya
Open Access
- 12 August 2020
- journal article
- research article
- Published by Springer Nature in BMC Pharmacology and Toxicology
- Vol. 21 (1) , 1-12
Abstract
Background: Cyclosporine A (CsA) is an essential immunosuppressant in organ transplantation. However, its chronic nephrotoxicity is an obstacle to long allograft survival that has not been overcome. Nuclear factor-κB (NF-κB) is activated in the renal tissue in CsA nephropathy. In this study, we aimed to investigate the effect of the specific NF-κB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), in a rat model of CsA nephrotoxicity.Methods: We administered CsA (15 mg/kg) daily for 28 days to Sprague-Dawley rats that underwent 5/6 nephrectomy under a low-salt diet. We administered DHMEQ (8 mg/kg) simultaneously with CsA to the treatment group, daily for 28 days and evaluated its effect on CsA nephrotoxicity.Results: DHMEQ significantly inhibited NF-κB activation and nuclear translocation due to CsA treatment. Elevated serum urea nitrogen and creatinine levels due to repeated CsA administration were significantly decreased by DHMEQ treatment (serum urea nitrogen in CsA + DHMEQ vs CsA vs control, 69 ± 6.4 vs 113.5 ± 8.8 vs 43.1 ± 1.1 mg/dL, respectively,p < 0.0001; serum creatinine in CsA + DHMEQ vs CsA vs control, 0.75 ± 0.02 vs 0.91 ± 0.02 vs 0.49 ± 0.02 mg/dL, respectively, p < 0.0001), and creatinine clearance was restored in the treatment group (CsA + DHMEQ vs CsA vs control, 2.57 ± 0.09 vs 1.94 ± 0.12 vs 4.61 ± 0.18 ml/min/kg, respectively, p < 0.0001). However, DHMEQ treatment did not alter the inhibitory effect of CsA on urinary protein secretion. The development of renal fibrosis due to chronic CsA nephrotoxicity was significantly inhibited by DHMEQ treatment (CsA + DHMEQ vs CsA vs control, 13.4 ± 7.1 vs 35.6 ± 18.4 vs 9.4 ± 5.4%, respectively, p < 0.0001), and these results reflected the results of renal functional assessment. DHMEQ treatment also had an inhibitory effect on the increased expression of chemokines, monocyte chemoattractant protein-1, and chemokine (c-c motif) ligand 5 due to repeated CsA administration, which inhibited the infiltration of macrophages and neutrophils into the renal tissue.Conclusions: These findings suggest that DHMEQ treatment in combination therapy with CsA-based immunosuppression is beneficial to prevent the development of CsA-induced nephrotoxicity.Keywords
All Related Versions
Funding Information
- Japan Society for the Promotion of Science (JP15K10649, JP19K09738)
This publication has 52 references indexed in Scilit:
- Smooth Muscle–Selective Inhibition of Nuclear Factor‐κB Attenuates Smooth Muscle Phenotypic Switching and Neointima Formation Following Vascular InjuryJournal of the American Heart Association, 2013
- Angiotensin II blockade upregulates the expression of Klotho, the anti-ageing gene, in an experimental model of chronic cyclosporine nephropathyNephrology Dialysis Transplantation, 2010
- Regulation of human dendritic cells by a novel specific nuclear factor–κB inhibitor, dehydroxymethylepoxyquinomicinHuman Immunology, 2010
- Inhibition of JAK2 protects renal endothelial and epithelial cells from oxidative stress and cyclosporin A toxicityKidney International, 2009
- Renal cell apoptosis induced by nephrotoxic drugs: cellular and molecular mechanisms and potential approaches to modulationApoptosis, 2007
- Inhibition of Tumor Necrosis Factor-α-induced Nuclear Translocation and Activation of NF-κB by DehydroxymethylepoxyquinomicinJournal of Biological Chemistry, 2002
- Vascular mechanisms of cyclosporin-induced hypertension in the rat.Journal of Clinical Investigation, 1994
- Molecular cloning of rat monocyte chemoattractant protein-1 (MCP-1) and its expression in rat spleen cells and tumor cell linesBiochemical and Biophysical Research Communications, 1991
- Cyclosporine-Associated Chronic NephropathyNew England Journal of Medicine, 1984
- CYCLOSPORIN A INITIALLY AS THE ONLY IMMUNOSUPPRESSANT IN 34 RECIPIENTS OF CADAVERIC ORGANS: 32 KIDNEYS, 2 PANCREASES, AND 2 LIVERSThe Lancet, 1979